Prime Medicine

First Trust Heitman Global Prime Real Estate ETF

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

Wall Street US stocks

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

EMKR

HRTG

PRME

PRTA

STLA

Dow Dips 300 Points; Emcore Shares Spike Higher

Challenges with Repatriating Oil Profits

Earnings

Long Ideas

Crude Oil Moves Higher; Prime Medicine Shares Spike Higher

Forex,Chart,On,Cityscape,With,Tall,Buildings,Background,Multi,Exposure.

Movers

CAPR

New Oriental Education & Technology Group

FUTU

GPCR

MNSO

TIGR

UXIN

Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday

Prime Medicine Inc

Health Care

Press Releases

Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies

Prime Medicine Unveils Strategically Focused Pipeline

General

Prime Medicine to Highlight New Preclinical Data, Including In Vivo Data in Wilson's Disease, at Upcoming Scientific Meetings

Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in its Wilson's Disease Program and the Broad Potential of its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress

Prime Medicine to Participate in Upcoming Investor Conferences

Prime Medicine Reports Third Quarter 2024 Financial Results and Provides Business Updates

Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference

Kuehn Law Encourages Investors of Prime Medicine, Inc. to Contact Law Firm

Prime Medicine to Present at TD Cowen 45th Annual Health Care Conference

Prime Medicine Reports Full Year 2024 Financial Results and Provides Business Updates

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Annexon

Astria Therapeutics

aTyr Pharma

Benitec Biopharma

Candel Therapeutics

Cidara Therapeutics

Celcuity

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Corvus Pharmaceuticals, Inc. - Common Stock

Corvus Pharma

Design Therapeutics

Emergent BioSolutions

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Gossamer Bio

Immutep Limited - American Depositary Shares

Immutep

ITeos Therapeutics

Anbio Biotechnology - Class A Ordinary Shares

Anbio Biotechnology

Olema Pharmaceuticals, Inc. - Common Stock

Olema Pharmaceuticals

Oruka Therapeutics

Regenxbio

Acelyrin

Tourmaline Bio

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

Verastem

Citizens Capital Markets

HC Wainwright & Co.

Chardan Capital

JMP Securities

Guggenheim

Comments

Prime Medicine

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga